Aarhus University Seal / Aarhus Universitets segl

Targets and Mechanisms in Prevention of Parkinson's Disease through Immunomodulatory Treatments

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisReviewForskningpeer review

Standard

Targets and Mechanisms in Prevention of Parkinson's Disease through Immunomodulatory Treatments. / von Euler Chelpin, M; Vorup-Jensen, T.

I: Scandinavian Journal of Immunology, Bind 85, Nr. 5, 2017, s. 321-330.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisReviewForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

von Euler Chelpin, M ; Vorup-Jensen, T. / Targets and Mechanisms in Prevention of Parkinson's Disease through Immunomodulatory Treatments. I: Scandinavian Journal of Immunology. 2017 ; Bind 85, Nr. 5. s. 321-330.

Bibtex

@article{5b935343642a4954ae1a3d9fe7fe4ecb,
title = "Targets and Mechanisms in Prevention of Parkinson's Disease through Immunomodulatory Treatments",
abstract = "Parkinson's disease (PD) is the second most common neurodegenerative disease in the world; however, there is no cure for it. Current treatments only relieve some of the symptoms, without ceasing the disease, and lose efficacy with prolonged treatment. Considerable evidence shows that persistent inflammatory responses, involving T cell infiltration and glial cell activation, are common characteristics of human patients and play a crucial role in the degeneration of dopaminergic neurons. Therefore, it is important to develop therapeutic strategies that can impede or halt the disease through the modulation of the peripheral immune system by aiming at controlling the existing neuroinflammation. Most of the immunomodulatory therapies designed for the treatment of Parkinson's disease are based on vaccines using AS or antibodies against it; yet, it is of significant interest to explore other formulations that could be used as therapeutic agents. Several vaccination procedures have shown that inducing regulatory T cells in the periphery is protective in PD animal models. In this regard, the formulation glatiramer acetate (Copaxone({\textregistered}) ), extensively used for the treatment of multiple sclerosis, could be a suitable candidate due to its capability to increase the number and suppressor capacity of regulatory T cells. In this review, we will present some of the recent immunomodulatory therapies for PD including vaccinations with AS or glatiramoids, or both, as treatments of PD pathology.",
keywords = "Adjuvants, Immunologic, Animals, Cytokines, Glatiramer Acetate, Humans, Models, Immunological, Molecular Targeted Therapy, Parkinson Disease, Th1 Cells, Th2 Cells, Journal Article, Review",
author = "{von Euler Chelpin}, M and T Vorup-Jensen",
note = "{\textcopyright} 2017 The Foundation for the Scandinavian Journal of Immunology.",
year = "2017",
doi = "10.1111/sji.12542",
language = "English",
volume = "85",
pages = "321--330",
journal = "Scandinavian Journal of Immunology",
issn = "0300-9475",
publisher = "Wiley-Blackwell Publishing Ltd.",
number = "5",

}

RIS

TY - JOUR

T1 - Targets and Mechanisms in Prevention of Parkinson's Disease through Immunomodulatory Treatments

AU - von Euler Chelpin, M

AU - Vorup-Jensen, T

N1 - © 2017 The Foundation for the Scandinavian Journal of Immunology.

PY - 2017

Y1 - 2017

N2 - Parkinson's disease (PD) is the second most common neurodegenerative disease in the world; however, there is no cure for it. Current treatments only relieve some of the symptoms, without ceasing the disease, and lose efficacy with prolonged treatment. Considerable evidence shows that persistent inflammatory responses, involving T cell infiltration and glial cell activation, are common characteristics of human patients and play a crucial role in the degeneration of dopaminergic neurons. Therefore, it is important to develop therapeutic strategies that can impede or halt the disease through the modulation of the peripheral immune system by aiming at controlling the existing neuroinflammation. Most of the immunomodulatory therapies designed for the treatment of Parkinson's disease are based on vaccines using AS or antibodies against it; yet, it is of significant interest to explore other formulations that could be used as therapeutic agents. Several vaccination procedures have shown that inducing regulatory T cells in the periphery is protective in PD animal models. In this regard, the formulation glatiramer acetate (Copaxone(®) ), extensively used for the treatment of multiple sclerosis, could be a suitable candidate due to its capability to increase the number and suppressor capacity of regulatory T cells. In this review, we will present some of the recent immunomodulatory therapies for PD including vaccinations with AS or glatiramoids, or both, as treatments of PD pathology.

AB - Parkinson's disease (PD) is the second most common neurodegenerative disease in the world; however, there is no cure for it. Current treatments only relieve some of the symptoms, without ceasing the disease, and lose efficacy with prolonged treatment. Considerable evidence shows that persistent inflammatory responses, involving T cell infiltration and glial cell activation, are common characteristics of human patients and play a crucial role in the degeneration of dopaminergic neurons. Therefore, it is important to develop therapeutic strategies that can impede or halt the disease through the modulation of the peripheral immune system by aiming at controlling the existing neuroinflammation. Most of the immunomodulatory therapies designed for the treatment of Parkinson's disease are based on vaccines using AS or antibodies against it; yet, it is of significant interest to explore other formulations that could be used as therapeutic agents. Several vaccination procedures have shown that inducing regulatory T cells in the periphery is protective in PD animal models. In this regard, the formulation glatiramer acetate (Copaxone(®) ), extensively used for the treatment of multiple sclerosis, could be a suitable candidate due to its capability to increase the number and suppressor capacity of regulatory T cells. In this review, we will present some of the recent immunomodulatory therapies for PD including vaccinations with AS or glatiramoids, or both, as treatments of PD pathology.

KW - Adjuvants, Immunologic

KW - Animals

KW - Cytokines

KW - Glatiramer Acetate

KW - Humans

KW - Models, Immunological

KW - Molecular Targeted Therapy

KW - Parkinson Disease

KW - Th1 Cells

KW - Th2 Cells

KW - Journal Article

KW - Review

U2 - 10.1111/sji.12542

DO - 10.1111/sji.12542

M3 - Review

C2 - 28231624

VL - 85

SP - 321

EP - 330

JO - Scandinavian Journal of Immunology

JF - Scandinavian Journal of Immunology

SN - 0300-9475

IS - 5

ER -